A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma

NCT05933967 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

The First Affiliated Hospital of Nanchang University

Interventions

DRUG: Orelabrutinib+R-CHOP

Sponsor

Shandong Cancer Hospital and Institute

Collaborators

[object Object]